

development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:**

Chris Kornak at 240-627-3705 or [Chris.Kornak@nih.gov](mailto:Chris.Kornak@nih.gov). Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

**SUPPLEMENTARY INFORMATION:**

Technology description follows:

**Replication-Competent Adenovirus Type-4 HIV Env Vaccines and Their Use**

*Description of Technology:* National Institute of Allergy and Infectious Diseases (NIAID), International AIDS Vaccine Initiative (IAVI), Emergent, and Scripps have developed two recombinant adenovirus type 4 (Ad4) vector-based vaccine candidates. These replicating Ad4 vector-based candidates have shown improved activity against tier 2 HIV-1 isolates in experimental animals. Tier 2 isolates are among the most prevalent in infected populations. The two candidates, Ad4-Env150KN and Ad4-Env145NFL, incorporate novel design features based on Ad4-EnvC150 (1086c). Specifically, the truncation of the cytoplasmic tail of Env increases cell surface expression and has resulted in improved antigenicity from both candidates.

Additionally, the upper respiratory tract administration offers a way to bypass pre-existing Ad4 immunity in most people. Furthermore, unlike non-replicating vectors, these vaccines may evoke a durable immune response.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

*Potential Commercial Applications*

- Prophylaxis against HIV-1.

*Competitive Advantages*

- Replicating vector may invoke durable immunity against HIV-1.
- Potential for prophylactic use in high-risk populations.
- Upper-respiratory (intranasal) administration will bypass pre-existing Ad4 immunity in most people.

*Development Stage*

- Phase 1 Clinical Trial (NCT03878121).

*Inventors:* Mark Connors (NIAID), Jeff Alexander (Emergent), Lo Vang (Emergent), Richard Wyatt (Scripps and IAVI), and Javier Guenaga (IAVI).

*Publications:* Alexander J., Mendy J., Vang L., Avanzini J.B., Garduno F., et al. (2013) Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C. PLOS ONE 8(12): e82380. <https://doi.org/10.1371/journal.pone.0082380>.

*Intellectual Property:* HHS Reference No. E-105-2020-0-PCT-01-PCT Application No. PCT/US21/45389 filed on 10 August 2021.

*Licensing Contact:* To license this technology, please contact Chris Kornak at 240-627-3705 or [Chris.Kornak@nih.gov](mailto:Chris.Kornak@nih.gov), and reference E-105-2020.

*Collaborative Research Opportunity:* The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. In particular, NIAID would be very interested in a partnership with an entity that has a complementary HIV vaccine technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or [Chris.Kornak@nih.gov](mailto:Chris.Kornak@nih.gov).

Dated: April 25, 2022.

**Surekha Vathyam,**

*Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2022-09158 Filed 4-27-22; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Office of the Secretary; Notice of Meeting**

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Interagency Pain Research Coordinating Committee.

The meeting will be open to the public via NIH Videocast <https://videocast.nih.gov/>. Individuals who plan to participate and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Interagency Pain Research Coordinating Committee.

*Date:* June 7, 2022.

*Time:* 2:00 p.m. to 5:00 p.m. Eastern Daylight Time (EDT).

*Agenda:* The meeting will cover committee business items and IPRCC member updates. Items discussed will include updates on pain workforce enhancement, pain research, patient engagement, and diversity efforts.

*Webcast Live:* <https://videocast.nih.gov/>.

*Deadline:* Submission of intent to submit written/electronic statement for comments: Tuesday, May 31st, by 5:00 p.m. EDT.

*Place:* National Institutes of Health, Building 31, 31 Center Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Linda L. Porter, Ph.D., Director, Office of Pain Policy and Planning, Office of the Director, National Institute of Neurological Disorders and Stroke, NIH, 31 Center Drive, Room 8A31, Bethesda, MD 20892, Phone: (301) 451-4460, Email: [Linda.Porter@nih.gov](mailto:Linda.Porter@nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Visit the IPRCC website for more information: <https://iprcc.nih.gov>. Agenda and any additional information for the meeting will be posted when available.

Dated: April 25, 2022.

**Tyeshia M. Roberson-Curtis,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2022-09140 Filed 4-27-22; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Engineered Influenza Neuraminidase Antigens**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive, sublicensable patent license to the University of Washington, located in Seattle, State of Washington, U.S.A. in its rights to the inventions and the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice.

**DATES:** Only written comments and/or applications for a license which are